The ADAURA study looked at the role of osimertinib as a treatment for resectable EGFR-mutated NSCLC after tumor removal. The results of this study have been explained in a new plain language summary published in Future Oncology.
Read the article for free here.
The original article, called “Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer,” was published in the New England Journal of Medicine. This article is free to read here.